Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study by Hubert G Nüßlein et al.
Nüßlein et al. BMC Musculoskeletal Disorders 2014, 15:14
http://www.biomedcentral.com/1471-2474/15/14RESEARCH ARTICLE Open AccessReal-world effectiveness of abatacept for
rheumatoid arthritis treatment in European
and Canadian populations: a 6-month
interim analysis of the 2-year, observational,
prospective ACTION study
Hubert G Nüßlein1*, Rieke Alten2, Mauro Galeazzi3, Hanns-Martin Lorenz4, Dimitrios Boumpas5,
Michael T Nurmohamed6, William G Bensen7, Gerd R Burmester8, Hans-Hartmut Peter9, Franz Rainer10,
Karel Pavelka11, Melanie Chartier12, Coralie Poncet13, Christiane Rauch14 and Manuela Le Bars15Abstract
Background: Discontinuation of rheumatoid arthritis (RA) treatment for lack or loss of initial response, tolerability issues,
or development of antibodies against the therapeutic agent remains a challenge in clinical practice. Here we present a
6-month interim analysis of a 2-year prospective observational trial in Europe and Canada aiming to assess the real-world
effectiveness, safety, and tolerability of intravenous abatacept for the treatment of moderate-to-severe RA.
Methods: ACTION (AbataCepT In rOutiNe clinical practice) is a prospective, observational study assessing effectiveness,
safety, and tolerability of abatacept in patients with RA enrolled in Europe and Canada between May 2008 and January
2011. The patient population was divided into two groups: biologic naïve (‘first-line’) patients and patients who had
previously failed treatment with at least one biologic agent (‘second-line’). Retention rates were calculated using
Kaplan–Meier curve estimates. Effectiveness was measured using European League Against Rheumatism (EULAR)
response criteria, the 28-item Disease Activity Score, the Clinical Disease Activity Index (CDAI), and physical function,
as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Serious adverse events (SAEs) were
reported for all enrolled patients.
Results: Of 1138 consecutively enrolled patients, 1114 and 1079 patients were evaluable for retention and effectiveness,
respectively. Overall, retention rates were 88.6% (95% confidence interval [CI]: 86.4, 90.4); 67.4% of patients achieved
good/moderate EULAR response; 32.8% had a CDAI Low Disease Activity State (LDAS); and 44.7% a HAQ-DI response.
Retention rates among first- and second-line patients were 93.0% (95% CI: 85.9, 96.6) and 88.1% (95% CI: 85.7, 90.0),
respectively. The percentage of patients achieving CDAI LDAS was 40.0% (95% CI: 26.4, 53.6) for first- and 32.2% (95% CI:
28.4, 36.0) for second-line patients and the proportion achieving a HAQ-DI response was 60.3% (95% CI: 47.8, 72.9)
versus 43.1% (95% CI: 39.0, 47.2), respectively. The incidence of SAEs was 4.7%.
Conclusions: Evidence from this 6-month interim analysis suggests that abatacept offers an effective and well-tolerated
treatment option for patients with RA, including those who have previously failed anti-tumor necrosis factor treatment.
In addition, higher retention rates and effectiveness outcomes were observed when abatacept treatment was initiated
earlier in the course of the disease.
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The treatment of rheumatoid arthritis (RA) in routine
clinical practice comprises both biologic and non-biologic
disease-modifying anti-rheumatic drugs (DMARDs), in-
cluding methotrexate (MTX) and tumor necrosis factor
(TNF) blocking agents. Although these treatments are
beneficial for many patients, some may not respond to
treatment or may lose their initial response over time [1].
Indeed, anti-TNF therapy discontinuation rates in real-
world practice are about 30%, based on cohort studies
with median follow-up of 15–37 months [2,3]. In these
studies, up to 50% of discontinuations were due to lack of
efficacy and approximately 15–49% to safety issues [2,3].
Patients who experience lack of efficacy with one anti-
TNF agent often have a poorer response to a second or
third anti-TNF agent, reflecting loss of efficacy and in-
creased resistance towards TNF-α blockade, which, in
some cases is due to the development of anti-therapeutic
antibodies [2-5]. This is demonstrated in several large co-
hort and retrospective studies by longer retention rates for
first treatment courses versus subsequent courses (hazard
ratio: 2.17; 95% confidence interval [CI]: 1.72, 2.58) and
decreased median drug survival times for subsequent anti-
TNF agents (37 months for first-line agent to 13 months
for third-line agent) [3,5]. Recent data suggest that when
treatment with an anti-TNF agent shows lack of efficacy,
switching to a biologic agent with a different mechanism
of action may be of benefit [6].
Randomized clinical trials (RCTs) of biologics have pro-
vided information on the efficacy, safety, and tolerability
of treatment options in different patient populations in a
clinical research setting. However, it has been reported
that treatment response rates are lower in routine clinical
practice compared with RCT evidence [7], possibly be-
cause of patient selection, the use of a washout period be-
fore inclusion, differences in dosing, comorbidities, and
variable adherence to therapy [7]. Because patient popula-
tions in observational studies are not subject to the strict
inclusion and exclusion criteria of RCTs, observational
studies often include patients with different levels of dis-
ease activity and region-specific variations in treatment.
Therefore, data from real-world observational studies
often supplement the findings from RCTs [8].
Abatacept is a selective T-cell costimulation modulator
[9]. Evidence from RCTs has demonstrated the efficacy,
safety, and tolerability of abatacept for the treatment of
moderate-to-severe RA in different patient populations
[10-14]. Moreover, evidence from local registries in
France [15], Denmark [16], and Sweden [17], as well as
evidence from a small, single-site study of abatacept in
routine clinical practice [18], support the findings from
RCTs. However, the observations from these small, ob-
servational cohorts need to be validated in a larger co-
hort of patients treated in routine clinical practice over alonger period of time. The objective of this report is to
present a 6-month interim analysis of the data from the
ACTION (AbataCepT In rOutiNe clinical practice)
study, a 2-year prospective, observational cohort study
that enrolled patients with RA in Europe and Canada to
evaluate patient retention and the effectiveness of treat-
ment with abatacept in routine clinical practice.
Methods
Study design and patient population
ACTION was a non-interventional, international, multi-
center, prospective, observational cohort study to evalu-
ate patient retention and the effectiveness of intravenous
abatacept treatment in patients with RA in Europe and
Canada. Patients were enrolled prospectively between
May 2008 and January 2011, either on, or within 3
months of, initiating treatment with abatacept according
to the Summary of Product Characteristics (SmPC) in
Europe and the Product Monograph in Canada. Patients
already on treatment with the study drug (169/1114
[15.2%]) were included only if baseline data were avail-
able and could be collected retrospectively.
In all participating countries, abatacept was required
to have market authorization and a reimbursement pol-
icy to ensure that eligible patients had access to the
drug. No product was provided to physicians or patients
by the study sponsor. This observational study did not
interfere with a physician’s routine clinical practice.
Moreover, the decision to treat a patient with abatacept
was made before their enrollment in the study. By using
a process of random selection from a comprehensive list
of rheumatologists, the investigators in each country
were geographically balanced and representative of rheu-
matologists who treat patients with biologics.
Enrolled patients provided informed written consent,
were over 18 years of age, of either gender, with an
established diagnosis of moderate-to-severe RA as de-
fined by the American College of Rheumatology revised
criteria 1987 [19]. Any patients already enrolled in an
interventional RA clinical trial were excluded. The study
protocol and patient enrollment were approved by ethics
committees and regulatory agencies in accordance with
each country’s requirements. The central ethics commit-
tee that first approved the study on 31 January 2008 was
the Munich, Bavaria, Germany ethics committee. For
each country, local ethics committee approvals were also
obtained, as required by local regulations.
The ACTION study was conducted in accordance
with the Declaration of Helsinki and was consistent with
the International Conference on Harmonization Good
Clinical Practice Guidelines [20] and Good Epidemio-
logical Practice Guidelines [21].
Each patient was followed for up to 2 years or, if the
patient discontinued abatacept treatment before the 2-
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continuation. Follow-up visits were approximately every
3 months. No formal assessment was performed to de-
fine reasons for prior treatment failure, other than those
reported by the treating physician.
Effectiveness assessments
Clinical characteristics and effectiveness are reported for
patients with data available at baseline and Month 6,
assessed no later than 8 days after the first abatacept in-
fusion. Previous studies have demonstrated that abata-
cept may have an impact on efficacy measures as early
as 7 days from the first infusion [22]. Patients who had
their clinical assessment more than 8 days after their
first abatacept infusion were not included in the effect-
iveness analysis. Disease activity was evaluated using the
28-item Disease Activity Score (DAS28), based either on
erythrocyte sedimentation rate (ESR) or C-reactive pro-
tein (CRP) [23,24] according to physician’s choice, and
Clinical Disease Activity Index (CDAI) [25]. Although
investigators could report disease activity outcomes
using the DAS28 and/or CDAI scores, in practice a ma-
jority of investigators reported only DAS28 scores; in
addition, the CDAI score was calculated from core com-
ponents collected for each patient. A sensitivity analysis
was conducted on data from patients for whom both
DAS28 and CDAI assessments were available and showed
that the effectiveness outcomes at Month 6 in these pa-
tients were similar to those in the overall population.
For DAS28, patients were classified as being in high
(>5.1), moderate (>3.2 and ≤5.1), or low disease activity
state (LDAS; ≤3.2), or remission (<2.6) [26]. LDAS was defi-
ned as a CDAI score ≤10, and remission was defined as a
CDAI score ≤2.8. European League Against Rheumatism
(EULAR) response was defined as good/moderate or no re-
sponse and was based on DAS28 (ESR) or DAS28 (CRP)
[27]. Physical function was assessed using the Health As-
sessment Questionnaire-Disability Index (HAQ-DI) [28].
HAQ response was defined as a mean change from baseline
in HAQ score of ≥0.3 units [29]; a clinically meaningful
change in physical function was defined as a mean change
from baseline in HAQ score of ≥0.22 units [29-31].
Safety assessments
Safety was evaluated in accordance with local regulations
and registered with the drug manufacturer’s global phar-
macovigilance department. Related treatment-emergent
adverse events (AEs) were assessed by the treating phys-
ician and reported to the pharmacovigilance department.
The relationship between the study drug and serious AE
(SAE) was judged by the treating physician. A SAE was
defined as an AE that was fatal or life-threatening, re-
quired or extended patient hospitalization (except preg-
nancy), resulted in persistent or significant disability orincapacity, induced a congenital anomaly or birth defect,
or was considered an important medical event. All deaths
were reported whether they were treatment-related or not.
Safety was presented for the entire enrolled population, re-
gardless of prior or concomitant treatment.
Statistical analyses
The patient population was stratified by prior line of
treatment into two subgroups: patients who were either
biologic-naïve prior to initiating abatacept (‘first-line’), or
patients who had previously received and failed at least
one biologic agent (‘second-line’); this second group in-
cluded patients initiating abatacept as a second- or
further-line of treatment. Additional subgroup analyses of
abatacept effectiveness and retention rates were performed
for second-line patients stratified according to the number
of prior anti-TNF agents failed (1 versus ≥2), the reason
for discontinuing their previous biologic agent (primary/
secondary inefficacy or safety and tolerability), or treat-
ment pattern at abatacept initiation (monotherapy or in
combination with conventional DMARDs). Baseline char-
acteristics and demographics are presented using descrip-
tive statistics for patients who received at least one
infusion of abatacept and had data related to abatacept ex-
posure. Retention on abatacept, defined as consecutive
time on treatment, was analyzed using a Kaplan–Meier
product limit estimator and is presented at Month 6 with
95% CIs. Patient discontinuation from abatacept treatment
was recorded by the physician at any follow-up visit. In
cases of abatacept discontinuation, exposure to abatacept
was defined as the time between the date of the first abata-
cept infusion and the date of the last abatacept infusion,
plus 30 days. Patients for whom data were not available at
6 months or who did not report abatacept discontinuation
were censored at the date of the last available data. Effect-
iveness analyses were ‘as-observed’ for patients on treat-
ment for whom data were available at each time point.
These data were presented as proportions with 95% CIs,
mean values, or changes with accompanying standard de-
viations (SDs) or 95% CIs.
Results
Patient disposition
Patient disposition is summarized in Figure 1. Of 1138 en-
rolled patients, 1114 (97.9%) were evaluable for the de-
scriptive analysis and retention rate calculation. Patients
were enrolled from nine countries (Austria, Belgium,
Canada, Czech Republic, Denmark, Germany, Greece,
Italy, The Netherlands) with the largest patient numbers
enrolled in Germany (n = 399), Italy (n = 236), Canada
(n = 229), and Greece (n = 149). A total of 96.9% (n =
1079/1114) of patients were evaluable for the effectiveness
analysis; comprising patients who had a baseline clinical as-
sessment on the same day/day before their first abatacept
Figure 1 Patient disposition. *Patients could provide more than one reason for discontinuation. DMARD, disease-modifying anti-rheumatic drug;
TNF, tumor necrosis factor.
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cept infusion (26.2% [n = 292]), ≤ 8 days after their first aba-
tacept infusion (1.4% [n = 16]), and patients with the date of
baseline clinical assessment missing (0.4% [n = 4]). Of the
35 (3.1%) patients who were not considered for the analysis
of effectiveness outcomes, 34 (3.1%) had a baseline assess-
ment between 8 days and 3 months following their first
abatacept infusion and 1 (<0.1%) patient >3 months later.
At the time of this analysis, approximately 86% of patients
had outcomes at Month 6 and 14% had either been lost to
follow-up at the data cut-off or their documentation had
not been received. Patient and disease characteristics at
abatacept initiation (baseline) were similar in patients with
and without available data at Month 6. A total of 118
(10.6%) evaluable patients were stratified to the ‘first-line’
treatment group, and 996 (89.4%) were stratified to the ‘sec-
ond-line’ treatment group.
A total of 112 patients in the overall population dis-
continued treatment within the first 6 months of the
study; 7 patients were in the first-line group and 105 pa-
tients were in the second-line group. Reasons for discon-
tinuation are shown in Figure 1.
Characterization of the patient population
Baseline demographic characteristics of the evaluable pa-
tients were similar between patients in either line-of-treatment group (Table 1). Mean disease duration was
shorter for patients in the first- versus second-line treat-
ment group (6.9 versus 11.5 years (Table 1); there were
more second-line treatment patients with disease dur-
ation longer than 6 years (68.8%) compared with the
first-line treatment group (38.8%).
The mean number of non-biologic DMARDs received
prior to enrolling in the study was 2.2 in the first-line
group received and 2.9 in the second-line group. Prior
treatment with corticosteroids or MTX was reported for
high and similar proportions of first- and second-line
patients (Table 1). Of the patients previously treated
with biologics (n = 996), 79.3% (n = 790) had previously
failed anti-TNF treatment only, and 18.9% (n = 188) had
treatment failures with both an anti-TNF and a non-
anti-TNF biologic. Of the 823 (84.1%) patients who re-
ceived anti-TNF therapy before enrolling in the study,
41.2% (n = 339) received adalimumab, 40.2% (n = 331)
etanercept, 17.1% (n = 141) infliximab, 0.9% (n = 7) cer-
tolizumab, and 0.6% (n = 5) golimumab. Of patients re-
ceiving treatment with non-anti-TNF biologics prior to
study enrollment, 9.7% (n = 95) were treated with rituxi-
mab and 4.6% (n = 45) with tocilizumab.
The mean number of biologic treatment failures for
second-line patients prior to initiating abatacept was
1.8. Among the 974 patients for whom reasons for
Table 1 Baseline demographics, disease and clinical characteristics by line-of-treatment category
Demographic characteristics N First-line n = 118 Second-line n = 996 Overall n = 1114
Age, mean (SD) 1113 59.1 (13.7) 56.2 (12.4) 56.5 (12.6)
Female, n (%) 1114 82 (69.5) 822 (82.5) 904 (81.1)
Weight, mean (SD) 1102 75.5 (15.9) 74.5 (17.0) 74.6 (16.9)
Disease characteristics
Mean disease duration, years (SD) 1079 6.9 (7.7) 11.5 (8.9) 11.0 (8.9)
Disease duration, n (%)
≤2 years 41 (35.3) 100 (10.4) 141 (13.1)
3–5 years 30 (25.9) 200 (20.8) 230 (21.3)
6–10 years 21 (18.1) 242 (25.1) 263 (24.4)
>10 years 24 (20.7) 421 (43.7) 445 (41.2)
Previous treatments
Previously treated with biologic agents, n (%) 1114 0 (0.0) 996 (100) 996 (89.4)
At least one anti-TNF agent, n (%) 0 (0.0) 978 (98.2) 978 (87.8)
Anti-TNF only 0 (0.0) 790 (79.3) 790 (70.9)
Anti-TNF and another biologic 0 (0.0) 188 (18.9) 188 (16.9)
Other mechanisms of action only 0 (0.0) 18 (1.8) 18 (1.6)
Number of prior anti-TNF agents, mean (SD) 0 (0.0) 1.6 (0.7) 1.4 (0.8)
One, n (%) 0 (0.0) 480 (48.2) 480 (43.1)
Two, n (%) 0 (0.0) 405 (40.7) 405 (36.4)
Three, n (%) 0 (0.0) 93 (9.3) 93 (8.3)
Clinical characteristics N* First-line N = 111 Second-line N = 968 Overall N = 1079
Tender joint count (28), mean (SD) 1052 11.5 (7.3) 11.4 (7.3) 11.4 (7.3)
Swollen joint count (28), mean (SD) 1069 9.5 (5.8) 7.8 (5.8) 8.0 (5.9)
Patient global assessment, mean (SD) (VAS 100 mm) 1002 61.9 (22.1) 66.2 (20.1) 65.8 (20.3)
Physician global assessment, mean (SD) (VAS 100 mm) 937 61.9 (18.7) 61.8 (19.4) 61.8 (19.3)
Patient global assessment of pain, mean (SD) (VAS 100 mm) 990 59.9 (24.5) 65.9 (20.7) 65.3 (21.1)
Patients with erosions, n (%) 926 58 (58.0) 590 (71.4) 648 (70.0)
DAS28 (ESR), mean (SD) 748 5.5 (1.3) 5.6 (1.2) 5.6 (1.2)
DAS28 (CRP), mean (SD) 216 4.8 (1.1) 5.2 (1.3) 5.2 (1.3)
CDAI, mean (SD) 919 33.4 (13.1) 31.5 (13.0) 31.7 (13.0)
SDAI, mean (SD) 824 35.4 (13.8) 33.9 (13.8) 34.0 (13.8)
HAQ-DI, mean (SD) 988 1.42 (0.59) 1.56 (0.67) 1.55 (0.67)
CRP mg/L, mean (SD) 943 19.6 (32.5) 24.4 (40.6) 23.9 (39.9)
ESR mm/hour, mean (SD) 988 32.5 (23.6) 35.5 (24.5) 35.2 (24.4)
Rheumatoid factor positive, n (%) 886 64 (68.1) 549 (69.3) 613 (69.2)
Anti-CCP positive, n (%) 598 36 (59.0) 354 (65.9) 390 (65.2)
*All patients with relevant baseline data assessed no later than 8 days after the first infusion of abatacept.
CCP, anti-cyclic citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation
rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; SD, standard deviation; SDAI, Simplified Disease Activity Index; TNF, tumor necrosis factor; VAS,
visual analog scale.
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ment were available, the reasons were: primary inefficacy
(26.6%, n = 259), loss of efficacy (secondary inefficacy)
(46.5%, n = 453), safety and tolerability (22.0%, n = 214),
other unspecified reasons (5.6%, n = 55), and achie-
ving remission or experiencing a major improvement(0.5%, n = 5). Patients could report more than one rea-
son for discontinuation of prior treatment before study
enrollment.
In the first-line treatment group (n = 118), 7.6% (n = 9)
of patients initiated abatacept as monotherapy and















































































































Figure 2 Kaplan–Meier estimated patient retention rates at
month 6. The estimate is given for each patient group with 95%
CIs. (A) Kaplan–Meier curves for the overall patient population, the
first-line group and the second-line group. (B) Kaplan–Meier curves
based on reasons for discontinuation of prior biologic therapy are
shown for patients who discontinued due to primary inefficacy,
secondary inefficacy, or safety and tolerability reasons. CI,
confidence interval.
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Abatacept was initiated in combination with corticoste-
roids in 64.4% (n = 76) of first-line patients. Of the 996
patients who had previously failed at least one biologic
agent, 22.8% (n = 227) received abatacept as monotherapy
and 77.2% (n = 769) received abatacept in combination
with another DMARD, of whom 61.0% (n = 469) received
abatacept in combination with MTX. Abatacept was initi-
ated in combination with corticosteroids in 74.9% (n =
746) of patients in the second-line treatment group.
Patient clinical characteristics by line-of-treatment
group are summarized in Table 1. The majority of pa-
tients were at high risk of disease progression: 58.0% in
the first-line group and 71.4% in the second-line group
had erosions, 59.0% of first-line and 65.9% of second-line
patients were anti-cyclic citrullinated protein positive, and
68.1% in the first-line and 69.3% in the second-line group
were rheumatoid factor (RF) positive. Overall, patients in
both treatment groups had high levels of disease severity
at baseline according to DAS28 (ESR), CDAI, and HAQ-
DI scores (Table 1).
Similar proportions of patients from both groups pre-
sented with at least one comorbidity at enrollment; most
commonly metabolic disorders (26.8%, n = 298), including
lipid metabolism and deposit disorders (not elsewhere clas-
sified [15.9%, n = 177]), and diabetes (12.1%, n = 135); endo-
crine disorders (14.2%, n = 158), including hypothyroidism
(10.1%, n = 112); respiratory disease (10.1%, n = 113); and
cardiac disorders (6.4%, n = 71). Infections and infestations
were reported by 5.9% (n = 66) of patients, including 1.4%
(n = 16) of patients with tuberculosis. Other comorbidities
at baseline included hepatobiliary disorders (2.3%, n = 26),
renal disorders (2.4%, n = 27), and neoplasms (benign, ma-
lignant, and unspecified; 2.6%, n = 29).
Retention rate
Retention rates in abatacept-treated patients are shown
in Figure 2. The Kaplan–Meier estimated retention rate
at endpoint (Day 169/Month 6) for all evaluable patients
(n = 1114) treated with abatacept was 88.6% (95% CI:
86.4, 90.4). For those in the first-line group, the reten-
tion rate was 93.0% (95% CI: 85.9, 96.6), whereas for pa-
tients in the second-line group it was 88.1% (95% CI:
85.7, 90.0) (Figure 2A).
For patients in the second-line group, the Kaplan–Meier
estimated retention rate at endpoint (Day 169/Month 6)
for patients initiating abatacept treatment after >1 prior
failed anti-TNF treatment was 89.2% (95% CI: 85.8, 91.8)
and for those who had failed ≥2 anti-TNF therapies it was
86.7% (95% CI: 83.1, 89.5). The Kaplan–Meier estimated
retention rates based on reasons for discontinuing prior
biologic therapy before initiating abatacept were 84.4%
(95% CI: 79.0, 88.6) for patients who discontinued due to
primary inefficacy, 90.3% (95% CI: 86.9, 92.8) for thosewho discontinued due to secondary inefficacy, and 85.1%
(95% CI: 79.1, 89.5) for those with safety and tolerability
issues with anti-TNF agents (Figure 2B). The estimated re-
tention rate was 87.7% (95% CI: 82.4, 91.5) for patients in
the second-line group who had received abatacept mono-
therapy and 88.1% (95% CI: 85.4, 90.4) for patients who
had received abatacept in combination with a DMARD at
initiation.
Effectiveness over 6 months
Changes in disease state were assessed using the DAS28
(ESR), DAS28 (CRP), and CDAI scores for patients in the
overall population with data evaluable for effectiveness at
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DAS28 (CRP), and CDAI scores were 5.5 (1.2), 5.2 (1.3),
and 31.7 (13.2), respectively, and mean (95% CI) changes
from baseline at Month 6 were −1.5 (−1.6, –1.3), –1.5
(−1.7, –1.2), and −15.2 (−16.3, –14.1), respectively (Table 2).
Patients receiving abatacept earlier in the course of treat-
ment (ie, first-line) achieved numerically greater mean
changes from baseline in DAS28 (ESR), DAS28 (CRP), and
CDAI compared with second-line abatacept, although 95%
CI overlapped (Table 2). Among second-line patients, mean
changes from baseline in DAS28 (ESR), DAS28 (CRP), and
CDAI were numerically greater among those who failed
one prior anti-TNF and those who failed ≥2, but with over-
lapping 95% CI (Table 2).
The proportions of patients achieving LDAS or remission
are shown in Figure 3A–C. The proportions achieving
LDAS or remission were higher by the DAS–CRP criteria.
By all criteria, a numerically higher proportion of first-line
patients achieved both LDAS and remission compared with
second-line patients. Among second-line patients, a numer-
ically higher proportion of patients who failed one prior
anti-TNF had achieved LDAS and remission, for all three
composite scales, compared with patients who had failed





DAS28 (ESR) 539 5.5 (1.2)
DAS28 (CRP) 151 5.2 (1.3)
CDAI 647 31.7 (13.2)
First-line
DAS28 (ESR) 33 5.2 (1.2)
DAS28 (CRP) 5 4.5 (1.3)
CDAI 48 31.9 (11.9)
Second-line
DAS28 (ESR) 506 5.6 (1.2)
DAS28 (CRP) 146 5.3 (1.3)
CDAI 599 31.7 (13.2)
One previous anti-TN
DAS28 (ESR) 247 5.5 (1.2)
DAS28 (CRP) 64 5.2 (1.3)
CDAI 291 30.6 (12.7)
≥2 previous anti-TNF
DAS28 (ESR) 251 5.6 (1.3)
DAS28 (CRP) 78 5.3 (1.4)
CDAI 295 32.5 (13.6)
CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein;
LDAS, low disease activity state; SD, standard deviation; TNF, tumor necrosis factor.The proportion of patients achieving a EULAR re-
sponse is shown in Figure 4. More than 67% of patients
achieved a good or moderate EULAR response, as de-
fined by DAS28 (ESR) or DAS28 (CRP) independently of
whether abatacept was initiated as first- or second-line
therapy (Figure 4). A good or moderate EULAR re-
sponse was achieved by similar proportions of patients
regardless of whether they had previously failed 1 or ≥2
anti-TNFs (69.2 and 64.5%, respectively).
Effectiveness was also stratified by reason for discon-
tinuation of patients with prior biologic therapy. Mean
change from baseline in DAS28 (ESR), DAS28 (CRP),
and CDAI was similar in patients who discontinued their
prior biologic due to primary inefficacy, secondary ineffi-
cacy, or safety and tolerability issues (Table 4). Slightly
different results were observed when considering LDAS
and remission (Table 4).
A good or moderate EULAR response was achieved by
similar proportions of patients regardless of the reasons
for which the last biologic therapy was discontinued
(67.2, 66.2, and 67.3% for those patients who discontin-
ued due to primary inefficacy, secondary inefficacy, or
intolerance, respectively). When comparing abatacept as
monotherapy versus in combination with a DMARD infied by line of therapy, and by number of previous
Change from baseline to month 6
Mean (95% CI)
473 −1.5 (−1.6, –1.3)
113 −1.5 (−1.7, –1.2)
605 −15.2 (−16.3, –14.1)
29 −1.7 (−2.3, –1.1)
4 −2.0 (−3.2, –0.8)
41 −18.3 (−22.0, –14.6)
444 −1.5 (−1.6, –1.3)
109 −1.4 (−1.7, –1.2)
564 −15.0 (−16.1, –13.9)
F
221 −1.6 (−1.8, –1.4)
46 −1.7 (−2.2, –1.2)
278 −15.0 (−16.5, –13.5)
s
216 −1.3 (−1.5, –1.1)
59 −1.2 (−1.6, –0.8)
275 −14.7 (−16.4, –12.9)
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Figure 3 Proportion of patients with LDAS or remission at baseline and at month 6. (A) Assessed by the DAS28 (ESR), (B) by the DAS28
(CRP), and (C) by the CDAI. LDAS was defined as a DAS28 score ≤3.2 or a CDAI score ≤10. Remission was defined as a DAS28 score <2.6 or a
CDAI score ≤2.8. Error bars represent 95% CI. *Includes patients receiving abatacept as a second- or further-line of treatment. CDAI, Clinical
Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; DAS28, 28-item Disease Activity Score; ESR, erythrocyte sedimentation rate;
LDAS, low disease activity state.
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63.1% (n = 65/103) versus 68.3% (n = 254/372) of pa-
tients achieved a good or moderate EULAR response,
27.5% (n = 38/138) versus 33.6% (n = 151/449) achieved
CDAI LDAS, and 5.1% (n = 7/138) versus 4.9% (n = 22/
449) achieved CDAI remission.
Among patients for whom data were available at
Month 6, the mean (SD) baseline HAQ-DI was 1.5 (0.6),
and the mean change in HAQ-DI score from baseline to
Month 6 was −0.30 (95% CI: –0.35, –0.26). After 6
months of abatacept treatment, 44.7% achieved a HAQ
response (≥0.3 unit change from baseline), and 55.0% ofpatients achieved a clinically meaningful change (≥0.22
unit change from baseline). Patients receiving abatacept
earlier in the course of treatment (ie, first-line) achieved
numerically greater mean changes from baseline in HAQ-
DI compared with second-line abatacept (−0.44, [95%
CI: –0.58, –0.29] versus −0.29 [95% CI: –0.34, –0.24], re-
spectively), although 95% CIs overlapped. A greater pro-
portion of first-line patients achieved a HAQ-DI response
compared with second-line patients (60.3% [95% CI: 47.8,
72.9] versus 43.1% [95% CI: 39.0, 47.2], respectively).
Among second-line patients, the mean change from base-
line in HAQ-DI (−0.35 [95% CI: –0.42, –0.28] versus −0.23
Table 3 Proportion of patients with LDAS* or remission
at baseline and at Month 6 for second line abatacept
stratified by 1 or ≥2 prior anti-TNF agent
Measure Remission at month 6 LDAS* at month 6
N Percent (95% CI) N Percent (95% CI)
One previous anti-TNF
DAS28 (ESR) 245 15.9 (11.3, 20.5) 245 29.8 (24.1, 35.5)
DAS28 (CRP) 57 22.8 (11.9, 33.7) 57 42.1 (29.3, 54.9)
CDAI 289 5.2 (2.6, 7.7) 289 35.6 (30.1, 41.2)
≥2 previous anti-TNFs
DAS28 (ESR) 234 12.8 (8.5, 17.1) 234 25.6 (20.0, 31.2)
DAS28 (CRP) 75 17.3 (8.8, 25.9) 75 33.3 (22.7, 44.0)
CDAI 286 4.9 (2.4, 7.4) 286 28.3 (23.1, 33.5)
*LDAS includes patients in remission (DAS remission: <2.6; CDAI
remission: ≤2.8).
CDAI, Clinical Disease Activity Index; DAS, Disease Activity Score; LDAS, Low
Disease Activity Score (≤3.2 for DAS and ≤10 for CDAI).
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http://www.biomedcentral.com/1471-2474/15/14[95% CI: –0.29, –0.17]) and the proportion of patients achi-
eving a HAQ-DI response (48.5 [95% CI: 42.6, 54.5] versus
37.1% [95% CI: 31.4, 42.8]) were greater among those
who failed one prior anti-TNF compared to those who
failed ≥2.
Concomitant medication
Overall, 822/1114 (73.8%) and 555/770 (72.1%) of pa-
tients were receiving concomitant corticosteroids at aba-
tacept initiation and at 6 months, respectively. The
median dose decreased from 7.5 mg/day (n = 724) to
5 mg/day (n = 494) over 6 months. Among those who
were on concomitant corticosteroids at abatacept initi-
ation and for whom 6-month data were available, 39/555
(7.0%) of patients discontinued all corticosteroids from













































Figure 4 Proportion of patients achieving a response at month
6 as defined by the EULAR. EULAR, European League
Against Rheumatism.a dose decrease from 10 mg/day (median dose at initi-
ation) to 5 mg/day (median dose at 6 months). Among
patients who were not on concomitant corticosteroids at
abatacept initiation and for whom 6-month data were
available, 39/215 (18.1%) of patients had concomitant
corticosteroids introduced to their treatment regimen
between abatacept initiation and Month 6; the median
dose at Month 6 was 7.5 mg/day. From initiation to
Month 6, 30/770 (3.9%) patients discontinued all con-
comitant DMARDs, whereas 20/770 (2.6%) patients had
concomitant DMARDs introduced during the first 6
months after abatacept initiation.
Safety
Safety was reported for all 1138 enrolled patients, and
no new or unexpected AEs were reported. SAEs were re-
ported in 4.7% (n = 54/1138) of patients and discontinu-
ations due to SAEs occurred in 1.8% (n = 20/1138) of
patients. Nine deaths were reported throughout the
study. Causes of death (n = 1, each) were: aspiration
pneumonia secondary to withdrawal from benzodiaze-
pines, asthma and stroke, seizure, heart attack, urosepsis,
suicide, Pneumocystis jiroveci pulmonary infection, sep-
sis, and unknown.
Serious infections were reported in 1.7% (n = 19) of pa-
tients. No cases of active tuberculosis were reported and
one case of opportunistic infection (Pneumocystis jiro-
veci) was reported but not confirmed by culture. Investi-
gators considered these infections to be unrelated to
treatment. Nine patients presented with malignancies
during the study that were not considered related to
treatment. Five patients had serious cardiac disorders
and three had vascular disorders (stroke, transient ische-
mic event, and deep-vein thrombosis). Diverticular per-
foration resulting in sepsis was reported in one patient,
for which surgery was performed. One severe acute sys-
temic infusion reaction as the result of an allergic reac-
tion was reported 25 minutes after beginning an
abatacept infusion. Pulmonary disorders were reported
in seven patients during the study, including one patient
with an event of bronchitis, who had known pre-existing
risk factors (tobacco use and grade II chronic obstructive
pulmonary disease).
Discussion
ACTION was the first international, non-interventional,
multicenter, prospective cohort study to evaluate patient
retention and effectiveness of abatacept treatment in pa-
tients with moderate-to-severe RA. The current interim
analysis evaluated a 6-month dataset from this ongoing
2-year study. This 6-month interim analysis may be par-
ticularly pertinent to clinicians because, according to the
treat-to-target approach, the decision to switch a bio-
logic therapy is usually made 3–6 months after initiating
Table 4 Subgroup analysis of second-line abatacept effectiveness by reasons for treatment failure
Measure Baseline Change from baseline to month 6 Remission at month 6 LDAS at month 6
N Mean (SD) N Mean (95% CI) N Percent (95% CI) N Percent (95% CI)
Primary inefficacy
DAS28 (ESR) 129 5.6 (1.3) 113 −1.5 (−1.7, –1.2) 119 17.6 (10.8, 24.5) 119 29.4 (21.2, 37.6)
DAS28 (CRP) 35 5.2 (1.3) 26 −1.3 (−2.0, –0.7) 32 12.5 (1.0, 24.0) 32 34.4 (17.9, 50.8)
CDAI 140 32.1 (13.1) 129 −13.9 (−16.3, –11.5) 136 2.9 (0.1, 5.8) 136 27.9 (20.4, 35.5)
Secondary inefficacy
DAS28 (ESR) 249 5.6 (1.1) 219 −1.4 (−1.6, –1.2) 240 10.4 (6.6, 14.3) 240 25.0 (19.5, 30.5)
DAS28 (CRP) 74 5.5 (1.3) 55 −1.6 (−2.0, –1.3) 68 20.6 (11.0, 30.2) 68 38.2 (26.7, 49.8)
CDAI 295 32.5 (13.0) 279 −15.4 (−17.1, –13.8) 288 4.2 (1.9, 6.5) 288 29.5 (24.2, 34.8)
Safety and tolerability
DAS28 (ESR) 91 5.5 (1.3) 84 −1.5 (−1.8, –1.2) 98 18.4 (10.7, 26.0) 98 29.6 (20.6, 38.6)
DAS28 (CRP) 27 4.8 (1.4) 22 −1.5 (−2.2, –0.9) 26 30.8 (13.0, 48.5) 26 42.3 (23.3, 61.3)
CDAI 121 30.4 (13.4) 115 −15.2 (−17.6, –12.8) 119 8.4 (3.4, 13.4) 119 38.7 (29.9, 47.4)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate.
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on abatacept, efficacy benefits with regards to disease ac-
tivity and physical function, and a safety profile consist-
ent with observations from both RCTs and local national
registries. Benefits were observed in biologic-naïve and
anti-TNF-refractory patients, regardless of the number
of previously failed anti-TNF agents, or whether failure
was due to primary or secondary inefficacy, or safety and
tolerability reasons. In the current study, approximately
70% of enrolled patients were RF positive, which is con-
sistent with the proportion of RF-positive patients en-
rolled in abatacept RCTs (ATTAIN study, 73.3%; ARRIVE,
61.3%) [13,32] and in real-life abatacept studies (ORA,
72.5%) [33].
It has been reported that treatment response rates are
often lower in routine clinical practice compared with
RCT evidence [7], as a result of the patient populations
in observational studies not being subject to the strict
inclusion and exclusion criteria of RCTs. However, the
heterogeneity of patient populations and disease charac-
teristics in observational studies provide a real-world
perspective of routine clinical practice. The efficacy,
safety, and tolerability of abatacept for the treatment of
moderate-to-severe RA have been demonstrated in
RCTs [10-14], in local national registries [15,16], and in
a small, single-site observational study [18]. Therefore, the
objective of the ACTION study was to translate the valid-
ity of RCT results into a real-life setting. Given the object-
ive of the study, a single-arm design was considered
appropriate to describe a cohort of patients treated with
abatacept and assess their drug utilization in accordance
with the European Medicines Agency and Health Tech-
nology Assessment Programmes’ recommendations.
Retention rates reported in the current trial were
high – >80.0% for second-line and 93.0% for first-linepatients – compared with evidence from other real-
world observational studies. Evidence from the Swedish
national registry ARTIS showed that, 1 year after initiat-
ing abatacept treatment, retention rates were 80% for
biologic-naïve patients and 64% for patients previously
treated with 1–2 biologics [17]. Similarly, 6-month re-
tention rates with abatacept treatment were 72.0% in the
Danish DANBIO registry [16] and 80.0% in a US obser-
vational study [18]. Although retention rates for RCTs
are expected to be higher than for real-world studies [7],
the retention rates in the current study were consistent
with an 82–90% retention rate reported from two abata-
cept RCTs, the ATTAIN and ARRIVE studies [13,32]. Of
note was the high retention rate for biologic-naïve pa-
tients in the current study (93.0%), which is consistent
with evidence from abatacept RCTs showing that patient
retention is higher when abatacept is initiated earlier in
the treatment regimen [11,14].
The efficacy of abatacept in the current report was
assessed using multiple disease activity measures (DAS28,
CDAI, and EULAR response); each of the clinical indices
showed the same trend for improved effectiveness with
abatacept, including the CDAI. Changes in disease activity
in the current study were consistent with those reported
in the DANBIO national registry [16] and the French
ORA registry [33]. A good-to-moderate treatment re-
sponse, as defined by EULAR, was achieved by more than
67% of both first- and second-line patients in the current
analysis; this was consistent with 6-month evidence from
the French ORA national registry [33] and the Danish
DANBIO registry [16]. In addition, response and remis-
sion rates with abatacept in the ACTION study were simi-
lar to those reported in the two previously mentioned
abatacept RCTs in patients with a prior inadequate re-
sponse to anti-TNF agents, the ATTAIN [13] and ARRIVE
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ing to the number of prior anti-TNFs failed or according
to the reason for discontinuation of the last biologic prior
to abatacept – highlight that abatacept has favorable safety
and tolerability in a real-world setting, regardless of the
number of prior anti-TNFs failed or the reason for failure.
These data support previously reported favorable out-
comes from the ARRIVE [32] trial in patients with similar
characteristics. Furthermore, the subgroup analyses in AC-
TION showed consistent numerically superior outcomes
for patients treated with abatacept earlier in their disease
course. As the study was not powered for subgroups ana-
lysis, definitive conclusions cannot be drawn.
Overall, no new safety signals were identified in the AC-
TION patient population compared with the safety profile
previously reported for abatacept from real-world studies
[16,18]. Of note is the absence of any cases of active tuber-
culosis and one report of opportunistic infection. It is im-
portant to note that a large number of patients enrolled in
the ACTION study had cardiovascular and pulmonary co-
morbidities, as well as chronic infections, at baseline,
reflecting the type of patient profile often found in routine
clinical practice compared with RCTs.
Although the results of some observational studies in-
dicate that, after the failure of 1 or ≥2 anti-TNF agents,
the choice of a biological agent with a different mechan-
ism of action may lead to better clinical outcomes, there
are a number of limitations associated with such ana-
lyses [34]. To our knowledge, there is little evidence
from real-life settings that directly compares abatacept
with another biologic agent or biologic agents with each
other. When interpreting the results of the current
study, there are a number of potential limitations to be
considered including lack of an active comparator and/
or selection bias based on factors such as disease sever-
ity or AEs. In addition, failure of multiple biologics prior
to abatacept treatment may have influenced physicians
to wait longer before deciding that a treatment was inef-
fective, potentially affecting the retention rate by Month
6. This interim analysis was also vulnerable to missing
data as none of the study assessments were mandatory;
thus, most missing clinical outcome data may have been
attributed to assessments not performed routinely at all
locations. Consequently, of the 24.7% of patients with
missing numerical DAS28 scores, 15.9% were reported
by the investigators as score ‘not calculated’. Here, we
report data ‘as observed’ with no imputation for missing
values, which is consistent with other non-interventional
studies.
Conclusions
This large, observational, real-world study demonstrated
high patient retention rates with abatacept treatment,regardless of line of treatment (first or second), the
number of previously failed anti-TNF agents, or the rea-
son for treatment failure. In addition, the data suggest
that patients treated earlier in their disease course with
abatacept have better outcomes than patients treated
after failure of one or more anti-TNF agents. Rates of re-
tention, LDAS, remission, HAQ-DI response, and safety
outcomes were consistent with data from both abatacept
RCTs and local national registries. Furthermore, in-
creased proportions of patients achieved remission or
LDAS after 6 months of abatacept treatment following
the failure of <2 anti-TNF agents, compared with those
who had failed ≥2 anti-TNF agents. The findings pre-
sented here underline that abatacept, when used alone
or in combination with DMARDs, provides a well-
tolerated and effective treatment option for patients with
RA, including those for whom previous anti-TNF treat-
ment has failed. These data further support the use of
abatacept monotherapy in clinical practice, as reflected
by observations from RA registries [6,33]. Future ana-
lyses of the ACTION study will evaluate the long-term
effectiveness, retention rates, and safety of abatacept in
the real-world setting.
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